PODD

Insulet Corp. reported strong financial results for Q1 2026, exceeding analyst expectations and raising its full-year 2026 total company revenue growth guidance to 21%-23%. However, the stock saw a premarket decline of 0.3% despite these strong earnings. A significant event impacting the stock was the recall of certain lots of its Omnipod 5 insulin patch pumps due to a manufacturing defect, which is expected to incur up to $40 million in costs in 2026. The company's stock has experienced a significant decline over the past year, with a 52-week range between $148.31 and $354.88.